Pakutanga kwaKurume, National Medical Products Administration yakabvumidza Jaypirca® (pirtobrutinib) yekurapa varwere vakuru vane chronic lymphocytic leukemia (CLL) kana small lymphocytic lymphoma (SLL) avo vakamborapwa kamwe chete kare, kusanganisira mushonga weBruton's tyrosine kinase (BTK) inhibitor.
Pirtobrutinib mushonga unodzivirira kinase zvakanyanya unoshandiswa nenzira itsva isina covalent binding kuti iwedzere kubatsirwa kwekutarisa nzira yeBTK muvarwere veCLL/SLL vakamborapwa nemushonga weBTK inhibitor (ibrutinib, acalabrutinib, kana zanubrutinib). Pirtobrutinib yakagamuchira mvumo kubva kuUS FDA muna Ndira 2023 semushonga weBTK unodzivirira non covalent (reversible). Muna Gumiguru 2024, pirtobrutinib yakatenderwa muChina semushonga mumwe chete wekurapa varwere vakuru vane relapse or refractory mantle cell lymphoma (MCL) avo vakambogamuchira mishonga miviri yapfuura, kusanganisira mushonga weBruton's tyrosine kinase (BTK).
Kubvumidzwa kwechiratidzo chitsva ichi kwakavakirwa pamhedzisiro yeongororo yepasi rose, ine nzvimbo dzakawanda, isina kurongeka, yeBRUIN CLL 321. BRUIN CLL 321 ndiyo yekutanga pasi rose yekuyedzwa kweChikamu chechitatu isina kurongeka yakaitwa muvarwere vane CLL/SLL vakamborapwa nemushonga wecovalent BTK inhibitor (cBTKi). Chidzidzo ichi chakanyoresa varwere vanosvika 238 uye chakaongorora kushanda uye kuchengetedzeka kwepirtobrutinib monotherapy zvichienzaniswa nesarudzo yemuongorori yeIdelaR (idelalisib plus rituximab) kana BR (bendamustine plus rituximab). Mhedzisiro yacho yakaratidza kuti pirtobrutinib yakawedzera zvakanyanya median progression free survival (PFS) zvichienzaniswa nesarudzo yemuongorori (mwedzi 14.0 vs mwedzi 8.7; hazard ratio [HR] = 0.54). Pamusoro pezvo, mwero wekurega mushonga nekuda kwezviitiko zvakaipa zvine chekuita nekurapwa wakaderera nekushandisa pirtobrutinib (5.2% vs 21.1%), zvichiwedzera kutsigira kushanda kwayo uye mabhenefiti ayo ekushivirira muvarwere vakamborapwa nemushonga weBTK unodzivirira covalent.
Taura Nesu Kuti Utange Rwendo Rwako rweTariro
Dhipatimendi reInternational Department reBeijing South Region Oncology Hospital rakatsaurira kupa varwere vepasi rose mukana wekurapwa kwekenza kwepamusoro-soro. Kana iwe kana nhengo yemhuri yako iri kutarisana nechirwere chekenza uye isina kupindura zvakakwana kumishonga yechinyakare, timu yedu yeInternational Patient Services yakagadzirira kukupa ruzivo rwakadzama uye zvirongwa zvekurapa zvinoenderana newe.
Ndapota taurai nesu kuburikidza nenzira dzinotevera kuti mudzidze zvakawanda nezvesarudzo dzekurapa kenza:
- Nhare: 400-880-3716
- WeChat: 17801183037
- Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)
Dhipatimendi reInternational Department reBeijing South Region Oncology Hospital rinotarisira kushanda pamwe chete nemi mukurwisa kenza. Pasinei nekuti muri kupi pasi rose, takazvipira kukupai rubatsiro rwekurapa rwehunyanzvi uye kutarisirwa netsitsi.
Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.
Nguva yekutumira: Kurume-12-2026